Co-led Reunion Neuroscience's $103M Series A financing alongside Novo Holdings to advance RE104 for postpartum depression.
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing innovative therapeutics for underserved mental health disorders, focusing on serotonergic medicines for conditions like depression and anxiety
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing innovative therapeutics for underserved mental health disorders, focusing on serotonergic medicines for conditions like depression and anxiety.